Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Shares, par value CHF 0.08 per share
-
Shares outstanding
-
124,261,423
-
Total 13F shares
-
54,883,537
-
Share change
-
+1,083,956
-
Total reported value
-
$172,881,709
-
Put/Call ratio
-
38%
-
Price per share
-
$3.15
-
Number of holders
-
76
-
Value change
-
+$3,394,419
-
Number of buys
-
48
-
Number of sells
-
24
Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q3 2024
As of 30 Sep 2024,
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) was held by
76 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,883,537 shares.
The largest 10 holders included
Redmile Group, LLC, Prosight Management, LP, ORBIMED ADVISORS LLC, BlackRock, Inc., MORGAN STANLEY, BANK OF AMERICA CORP /DE/, SILVERARC CAPITAL MANAGEMENT, LLC, GOLDMAN SACHS GROUP INC, PLATINUM INVESTMENT MANAGEMENT LTD, and Siren, L.L.C..
This page lists
76
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.